Stoke Therapeutics, Inc. has experienced a notable change in its shareholder structure as Morgan Stanley has amended its ownership stake in the company. According to a recent filing, Morgan Stanley has reduced its beneficial ownership of Stoke's common stock to below five percent. This shift is significant as it may impact the company's future strategies and market perception.

Background

Stoke Therapeutics is a biotechnology company focused on developing therapies for genetic diseases. It operates under the SIC classification of Pharmaceutical Preparations (SIC 2834) and is listed on the Nasdaq under the ticker symbol STOK. The company has been actively filing various forms with the SEC, including recent submissions that highlight its operational activities and financial performance.

What the Filing Says

The Schedule 13G/A filing, dated November 13, 2026, indicates that Morgan Stanley has ceased to be the beneficial owner of more than five percent of Stoke Therapeutics' common stock. The filing states: "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities." This marks a significant reduction in their holdings.

Impact

This change in ownership may affect various stakeholders, including current and potential investors, as well as the management team at Stoke Therapeutics. The reduction in stake by a major financial institution like Morgan Stanley could lead to shifts in market sentiment and influence other investors' decisions regarding Stoke's stock.

What's Next

The filing does not say what happens next.